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Previewsin vivo, and forms large nuclear foci con-
taining p300 and acetylated histones
(Saint Just Ribeiro and Wallberg, 2009).
MAML1 also interacts directly with CDK8,
which, likeMAML1, is required for transac-
tivation by p53 (Donner et al., 2007) and
beta-catenin (Firestein and Hahn, 2009).
Coexpression of MAML1 with NICD and
CSL proteins in cells induces proteolytic
destruction of NICD, indicating that it
might also help in the disassembly of the
enhancer complex following signaling.
Thus MAML1 may serve as a scaffold to
integrate the activities of multiple enzy-
matic complexes in transcription.
The various activities of the Master-
mind-like coactivators illustrate the great
utility of the approach used by Moellering
et al. (2009). Whereas transcription would
be affected broadly by targeted elimina-
tion of MAML1 or chemical inhibiton of
p300 or CDK8, themore selective SAHM1
peptide may simply uncouple MAML1
from the Notch pathway while leaving its
other activities intact. A central question
then is whether the SAHM1 peptide might752 Developmental Cell 17, December 15, 20also block binding of MAML1 to p53,
beta-catenin, or other activators. SAHM1
might be expected to also block growth
of colon cancer cells, which depends
upon Notch as well as Wnt/beta-catenin
signaling (van Es et al., 2005). However,
the utility of this peptide could be com-
promised if it is found to disrupt trans-
cription by p53 or other tumor suppres-
sors. Therefore to better appreciate the
potential therapeutic utility of SAHM1
peptides, it will be important to define
how MAML1 functions in other signaling
pathways.
These new findings from Bradner and
colleagues provide an important ‘‘proof
of principle’’ that effective domain-selec-
tive disruption of regulatory protein inter-
actions is achievable both in cells and in
animals. Looking forward, this elegant
new technology could be used to block
other critical developmental and cancer
signaling pathways, or to inhibit viral
proteins that selectively engage host cell
factors to promote virus replication in
infectious diseases or cancer.09 ª2009 Elsevier Inc.REFERENCES
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In this issue of Developmental Cell, Suizu et al. (2009) describe a new mechanism for posttranslational
regulation of the Akt serine/threonine protein kinase involving ubiquitination. They show that the E3 ubiquitin
ligase TTC3 modifies phosphorylated and activated Akt and thereby promotes its degradation by the
proteasome in the nucleus.The phosphoinositide 3-kinase (PI3K) and
Akt (also known as protein kinase B [PKB])
signaling pathway controls a variety of
cellular phenotypes. Somatic mutations
in multiple enzymes in the PI3K signaling
cascade have been linked to a variety of
human pathophysiological conditions,
most notably cancer (Engelman, 2009).
At this point, multiple phase I and phase
II clinical trials are underway with small
molecule inhibitors targeting one or more
enzymes in the pathway. In their study,
Suizu et al. (2009) uncover a new facetof Akt regulation and reveal a mechanism
for termination of Akt signaling in the
nucleus that is mediated by the E3 ubiqui-
tin ligase TTC3.
The basic mechanism of Akt activation
in response to growth factor stimulation is
well understood. The first and rate-limiting
step is translocation to the membrane,
where Akt directly binds to the PI3K lipid
PtdIns-3,4,5-P3. A conformational change
exposes two residues, Thr308 in the acti-
vation loop, which is phosphorylated by
the phosphoinositide-dependent kinase1 (PDK-1), and carboxyl-terminal Ser473,
which is phosphorylated by the mamma-
lian target of rapamycin complex 2
(mTORC2) (Figure 1). Once phosphory-
lated, activated Akt translocates to
multiple intracellular locations, including
the nucleus. Over 130 substrates of Akt
have been identified that transduce the
signal to a variety of cellular responses
(Manning andCantley, 2007). The defining
feature of Akt-mediated phosphorylation
is a consensus motif on substrates com-
prising Arg-X-Arg-X-X-Ser/Thr, where X
Figure 1. Ubiquitination Regulates the Activation and Inactivation of Akt
Growth factors stimulate PI3K activation and increase PtdIns-3,4,5-P3 accumulation at the plasma
membrane. This leads to recruitment of PDK-1 and Akt. Akt recruitment is also facilitated by monoubiqui-
tination mediated by TRAF6. Akt is then phosphorylated at Thr308 and Ser473 by PDK-1 and mTORC2,
respectively. Phosphorylated Akt then translocates to the cytoplasm where it phosphorylates substrates
and mediates signal relay. Akt also translocates to the nucleus where it encounters additional substrates,
including TTC3. Phosphorylation increases TTC3 E3 ubiquitin ligase activity and this in turn induces Akt
polyubiquitination and subsequent degradation by the nuclear proteasome. The net effect is termination
of Akt signaling. (Green arrows denote direct phosphorylation reactions, red denote ubiquitination
reactions).
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Previewsrepresents any amino acid. Other protein
kinases that belong to the AGC (protein
kinases A, G and C) family also phosphor-
ylate the same consensus motif, and
overlapping phosphorylation of the same
motif on substrates by multiple AGC
kinases has been reported (Zhang et al.,
2006).
Hyperactivation of Akt is a common
feature of many human solid tumors
(Manning and Cantley, 2007). Deregu-
lated PI3K and Akt signaling can also
result from genetic lesions in enzymes
that terminate signal relay. These include
PTEN, a PtdIns-3,4,5-P3 phosphatase
and tumor suppressor that is subject to
mutations, deletions, or LOH in many
cancers (Keniry and Parsons, 2008).
Loss of PTEN activity results in accumula-
tion of PtdIns-3,4,5-P3 and hyperactiva-
tion of Akt. Similarly, the serine/threonine
phosphatase PHLPP (PH domain and
leucine-containing protein phosphatase)
specifically dephosphorylates pSer473 in
Akt, thereby dampening Akt activity (Gaoet al., 2005). Again, inactivating mutations
or deletion in PHLPP results in deregu-
lated Akt signaling. Understanding the
mechanism of Akt activation and inactiva-
tion is important from a drug discovery
perspective, since itmayaffordnovel ther-
apeutic targets for clinical intervention.
Protein modification by ubiquitination
is a common posttranslational modifica-
tion that can function to promote either
protein degradation by the 26S protea-
some or alternatively promote interac-
tions with other proteins to induce signal
relay. In their paper, Suizu et al. (2009)
report on a mechanism of termination of
Akt signaling that involves ubiquitination
and proteasome-mediated degradation.
Using a two-hybrid interaction screen,
they found that Akt interacts with TTC3
(tetratricopeptide repeat domain 3), an
E3 ubiquitin ligase. Both in vitro and in
cells, TTC3 interacts with and ubiquiti-
nates Akt (Figure 1). Three isoforms of Akt
exist in mammals, Akt1, Akt2 and Akt3,
and recent studies have pointed to iso-Developmental Cell 17, Dform-specific functions in cancer progres-
sion (Chin and Toker, 2009). TTC3 inter-
acts with all three Akt proteins and
presumably targets them all for degrada-
tion, although ubiquitination was only
shown for Akt2 in the current study. Inter-
estingly, the authors report that TTC3
specifically interacts with and ubiquiti-
nates fully phosphorylated and activated
Akt, indicating that it functions as a mech-
anism for terminating Akt signaling after
activation. Thismodel is further supported
by the finding that Akt phosphorylates
TTC3 at Ser378, and that in turn this is
required for ubiquitin ligase activity. Thus,
Akt activation leads to the phosphoryla-
tion and activation of its own E3 ligase,
which ultimately leads to Akt destruction
by the proteasome. TTC3 Ser378 does
not conform to the classic Akt consensus
motif noted above, as it lacks the 5 Arg
residue. As the authors point out, a few
other Akt substrates have been identified
that also lack this residue. Thus, while
Akt might be the TTC3 kinase relevant
for Ser378 phosphorylation, other AGC
kinases such as S6K, SGK, and RSK
could also be involved.
Modification of Akt by ubiquitination is
not a novel concept. Phosphorylation of
Akt has previously been linked to protein
stability (Facchinetti et al., 2008), and
other E3 ligases also target Akt, including
BRCA1, CHIP, and particularly TRAF6
(Yang et al., 2009). However, the mecha-
nism by which these E3 ligases interact
with the Akt pathway is distinct from that
of TTC3. TRAF6 mono-ubiquitinates Akt
before phosphorylation, and this modifi-
cation is necessary for translocation and
activation of Akt (Figure 1). In contrast,
TTC3 functions downstream of Akt
activation, as it binds to phosphorylated
Akt and promotes its degradation. Cells
lacking TTC3 show enhanced Akt phos-
phorylation and signaling. Thus, two
distinct E3 ligases are required for the
efficient activation and inactivation of Akt,
and interfering with these ubiquitin ligases
has profound consequences for down-
stream signal relay and cellular pheno-
types associated with the Akt pathway.
Another important finding made by
Suizu et al. (2009) is that TTC3-mediated
ubiquitination and degradation appears
to occur in the nucleus. It is well
documented that activated Akt is present
in the nucleus, and most human solid
tumors show phosphorylated Akt in theecember 15, 2009 ª2009 Elsevier Inc. 753
Developmental Cell
Previewsnucleus as well as at the plasma
membrane. Whether there is a resident
pool of Akt that is activated by nuclear
PI3K signaling, or whether Akt that is
activated at the membrane then translo-
cates to the nucleus is still the subject
of some debate (Martelli et al., 2006).
Regardless, Suizu et al. (2009) show that
TTC3 targets nuclear Akt for ubiquitina-
tion and degradation more efficiently
than the cytoplasmic pool. The fact that
TTC3 has two nuclear localization
sequences suggests that it might trans-
port Akt to the nucleus for degradation
by the nuclear proteasomal system. Alter-
natively, Akt might translocate to the
nucleus by an independent mechanism
where it encounters its substrates,
including TTC3, leading to its ubiquitina-
tion and degradation (Figure 1). Regard-
less, there is a growing body of evidence
indicating that Akt plays a major role in
nuclear signaling. These findings show
that Akt signal termination also occurs in
this compartment.
In summary, the findings from Suizu
et al. (2009) have identified yet another754 Developmental Cell 17, December 15, 20level of regulation of the Akt kinase that
involves termination of signaling via
proteasomal degradation in the nucleus.
Whether TTC3 represents the primary
mechanism for termination of Akt
signaling by degradation remains to be
determined. Similarly, the relevance of
TTC3 regulation of Akt in human cancer
progression remains to be established. A
final interesting connection is that TTC3
is one of the supernumerary genes in the
Down’s syndrome critical region (DSCR),
suggesting a potential link between Akt
signaling and the symptoms associated
with this disorder. Consistent with this
idea, cells derived fromDown’s syndrome
patients reveal a modest upregulation of
TTC3 and also display reduced Akt levels
and accumulation at the G2Mphase of the
cell cycle. Although the relevance of TTC3
and Akt interactions to Down’s syndrome
remains to be established, it clearly
warrants further investigation and raises
the tantalizing possibility that the Akt
pathway might be a relevant pharmaco-
logical target for this common human
genetic disorder.09 ª2009 Elsevier Inc.REFERENCES
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